Where companies see opportunity in the crowded PD-1 marketplace

Everyone wants a piece of the PD-1 pie, but as Merck continues to snap up new indications for Keytruda and the number of competitors grows, carving out niches in the competitive landscape is becoming increasingly difficult.

Still, companies are chipping away at the market leader’s stronghold, deploying a range of strategies to create new markets. The new frontier is indications that were initially labeled too “cold” for the checkpoint inhibitor therapy; the task at hand is to find subgroups within those challenging tumor types that stand to benefit from the treatment. ...